TSI-01
TSI-01 is a pro-inflammatory phospholipid mediator that is rapidly synthesized by lyso-PAF acetyltransferase (lyso-PAFAT) in response to extracellular stimuli. Two types of lyso-PAFAT have been identified: lysophosphatidylcholine acyltransferase (LPCAT) 1, which is mostly expressed in the lungs, and LPCAT2, which is expressed in inflammatory cells. TSI-01 is a selective inhibitor of LPCAT2 (IC50s=0.47 versus 3.02 μM for human LPCAT2 and LPCAT1, respectively) . 60 μM it is shown to suppress PAF biosynthesis in mouse peritoneal macrophages stimulated with a calcium ionophore.
Product Specifications
CAS Number
704878-75-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Platelet-activating Factor Receptor (PAFR)
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tsi-01.html
Purity
98.52
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C(N2C(C(Cl)=C(C2=O)Cl)=O)C=C1)OC(C)C
Molecular Formula
C14H11Cl2NO4
Molecular Weight
328.15
Precautions
H302, H315, H319, H335
References & Citations
[1]Tarui, et al. Selective inhibitors of a PAF biosynthetic enzyme lysophosphatidylcholine acyltransferase 2. J. Lipid Res. 55 (7), 1386-1396 (2014) .
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SOHLH1 Antibody - C-terminal region : FITC (ARP54547_P050-FITC)
Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine)
